-
2023-503831-17-00
4
2019-12-23
The treatment of participants with HRRm and/or HRD-positive cancer
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2022-501102-35-00
5
2019-12-02
Early triple negative breast cancer
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2024-510887-22-00
5
2019-09-30
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
-
2023-509019-97-00
9
2019-07-15
Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years o
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2024-513430-37-00
6
2019-06-01
Facial Nerve Palsy (Bells Palsy)
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2024-512585-34-00
4
2019-02-27
Indolent Systemic Mastocytosis (ISM)
-
2024-517417-32-00
4
2018-11-22
CHRONIC MYELOID LEUKEMIA
-
2023-508551-40-00
6
2018-06-08
Coronary artery multi-vessel disease and left main stenosis
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2023-504802-12-00
7
2018-05-16
Lymphoma of B-cell origin
-
2024-510630-40-00
5
2018-02-12
Multiple sclerosis
-
2024-514275-18-00
10
2017-12-06
Mantle Cell Lymphoma (MCL)
-
2024-517448-79-00
5
2017-11-23
Heart failure with preserved ejection fraction
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-510159-53-01
4
2017-09-28
peritoneal dissemination in stomach cancer patients
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2024-517321-99-00
4
2016-08-01
Myeloma multiplex
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine